Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Moving to the frontline: gilteritinib plus chemo for newly diagnosed AML

Alexander Perl • 15 Jun 2019
EHA 2019
Acute Myeloid Leukemia Leukemia Gilteritinib

Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, explains the updated results from the Phase I study (NCT02236013) of gilteritinib in combination with induction and consolidation therapy in newly diagnosed acute myeloid leukemia (AML). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Alexander Perl

3:03
QuANTUM-First: FLT3-ITD-specific MRD to assess benefits of quizartinib in FLT3-ITD+ AML
Alexander Perl • 9 Dec 2023
2:46
Update of the ADMIRAL trial: gilteritinib vs salvage chemotherapy prior to HSCT in FLT-3 mutated AML
Alexander Perl • 9 Dec 2023
2:07
Comparing midostaurin to next-generation FLT3 inhibitors in the frontline treatment of FLT3-ITD AML
Alexander Perl • 9 Jun 2023
0:44
The clinical meaning of MRD below the threshold of mCR in AML
Alexander Perl • 9 Jun 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals